(Q52971040)

10 May 2018

title

Expression of TRAIL receptors in human autoreactive and foreign antigen-specific T cells. (English)

1 reference

10 May 2018

author

Frauke Zipp

7

1 reference

10 May 2018

author name string

U Wendling

1

1 reference

10 May 2018

H Walczak

2

1 reference

10 May 2018

J Dörr

3

1 reference

10 May 2018

C Jaboci

4

1 reference

10 May 2018

M Weller

5

1 reference

10 May 2018

P H Krammer

6

1 reference

10 May 2018

publication date

1 July 2000

1 reference

10 May 2018

Cell Death & Differentiation

published in

1 reference

10 May 2018

volume

7

1 reference

10 May 2018

issue

7

1 reference

10 May 2018

page(s)

637-644

1 reference

10 May 2018

https://scigraph.springernature.com/pub.10.1038/sj.cdd.4400692

exact match

0 references

cites work

Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

Activation-induced apoptosis of autoreactive and alloreactive T lymphocytes in the target organ as a major mechanism of tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

Fas ligand mediates activation-induced cell death in human T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

Multiple sclerosis: Fas signaling in oligodendrocyte cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

Immune (dys)regulation in multiple sclerosis: role of the CD95-CD95 ligand system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

Soluble antigen therapy induces apoptosis of autoreactive T cells preferentially in the target organ rather than in the peripheral lymphoid organs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

Myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis is chronic/relapsing in perforin knockout mice, but monophasic in Fas- and Fas ligand-deficient lpr and gld mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

Serum CD95 of relapsing remitting multiple sclerosis patients protects from CD95-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

Soluble Fas (Apo-1) levels in cerebrospinal fluid of multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

Dual role for Fas ligand in the initiation of and recovery from experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

Activation interferes with the APO-1 pathway in mature human T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

Identification and characterization of a new member of the TNF family that induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

The receptor for the cytotoxic ligand TRAIL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

An antagonist decoy receptor and a death domain-containing receptor for TRAIL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

A novel receptor for Apo2L/TRAIL contains a truncated death domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

TRAIL/Apo-2-ligand-induced apoptosis in human T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

APO2 ligand: a novel lethal weapon against malignant glioma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

Clinical, immunological, and pathological consequences of Fas-deficient conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

The role of autoimmune T lymphocytes in the pathogenesis of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

Immunological aspects of demyelinating diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

Monoclonal antibody-mediated tumor regression by induction of apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

Resistance of cultured peripheral T cells towards activation-induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death-inducing signaling complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

7 January 2021

Bisindolylmaleimide VIII facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

7 January 2021

Impaired apoptosis in mitogen-stimulated lymphocytes of patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

7 January 2021

Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

7 January 2021

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

7 January 2021

Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400692

7 January 2021

Identifiers

DOI

10.1038/SJ.CDD.4400692

1 reference

10 May 2018

Dimensions Publication ID

1039622889

0 references

1 reference

10 May 2018